| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03967288 Details | 2024-02-16 Interventional | 4 | 27 | Bupivacaine Chloroprocaine Procaine Anesthesia, Spi… | Four patients required conversion to GETA (2 in each study arm) - | |||
| NCT03940690 Details | 2024-02-16 Interventional | 3 | - | Bevacizumab Retinal Telangi… Telangiectasis Coats Disease | awaiting results of interim analysis - | |||
| NCT02315157 Details | 2024-02-16 Interventional | 1 | 0 | Bendamustine Hy… Leukemia, Plasm… Multiple Myelom… Neoplasms, Plas… Plasma Cell Leu… | Withdrawn by PI - | |||
| NCT06018116 Details | 2024-02-15 Interventional | 2 | 0 | Antibodies, Mon… Avelumab Bicalutamide Carcinoma, Tran… Metastatic Urot… | Results of EV302 study do not make it feasible to complete a study in second line avelumab
immunotherapy. The new standard of care make this study not pertinent. - | |||
| NCT05378763 Details | 2024-02-15 Interventional | 3 | - | Docetaxel Carcinoma, Non-… NSCLC | The study has not enrolled any patients. The study design is under discussion and will likely
be redesigned in consultation with the FDA. - | |||
| NCT04428333 2019-003981-42 Details | 2024-02-15 Interventional | 2/3 | 118 | Fluorouracil Pembrolizumab Carcinoma Carcinoma, Squa… Head and Neck N… Squamous Cell C… Neoplasms, Head… | The trial was stopped by the sponsor based on assessment of the clinical data Data are reported following the interim analysis decision to stop further accrual into the study and discontinue feladilimab/placebo. The study primary completion analysis results should be interpreted with consideration of the immature data | |||
| NCT04341311 Details | 2024-02-15 Interventional | 1 | 4 | Panobinostat Brain Neoplasms Diffuse Intrins… Glioma Gliosarcoma Diffuse Glioma Pediatric Brain… Pediatric Brain… Pediatric Brain… Pediatric Cance… | Withdrawal of support from BMS - | |||
| NCT03818776 Details | 2024-02-15 Interventional | 1 | 7 | Durvalumab Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | Safety - | |||
| NCT06259630 Details | 2024-02-14 Interventional | 4 | 0 | Nicotine Tobacco Use Dis… Nicotine Addict… Nicotine Use Di… | Investigators no longer wanted to pursue this research topic - | |||
| NCT05379179 Details | 2024-02-14 Interventional | 4 | 3 | Fentanyl Ketamine Poisoning Rattlesnake Env… | After 20 months of active enrollment and a lack of qualified/interested subjects, the
Investigator, Meghan Spyres, MD, decided to terminate recruitment before meeting the stated
enrollment objectives. Significant limitations were not reaching the target number of patients, extremely low enrollment resulted in termination. | |||
| NCT05219604 Details | 2024-02-14 Interventional | 4 | 3 | Diphenhydramine Promethazine Central Nervous… Pharmacokinetic… | Institution decision - | |||
| NCT04814875 Details | 2024-02-14 Interventional | 1/2 | 16 | Carboplatin Doxorubicin Liposomal doxor… Carcinoma Carcinoma, Endo… Carcinoma, Ovar… Fallopian Tube … Fallopian Tube … High Grade Seri… Ovarian Cancer Primary Periton… | For technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study,
AM ATX101-03, immediately. - | |||
| NCT04652518 Details | 2024-02-14 Interventional | 2 | 185 | Pirfenidone COVID-19 Respiration Dis… Respiratory Tra… Covid19 Post-acute COVI… | Part A of the study was completed; Part B of the study was terminated - | |||
| NCT03958383 Details | 2024-02-14 Interventional | 1/2 | - | Ipilimumab Nivolumab Melanoma | Administrative - | |||
| NCT03179995 Details | 2024-02-14 Interventional | 2 | 23 | Octreotide Major Liver Res… | Grantor closed study - | |||
| NCT06113289 Details | 2024-02-13 Interventional | 1/2 | - | Decitabine and … Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | PI Request - | |||
| NCT04533737 2019-004099-20 Details | 2024-02-13 Interventional | 4 | [1 Refs] | 113 | Brodalumab Psoriasis Plaque Psoriasi… Psoriasis Vulga… | The recruitment was terminated early due to delays and slow recruitment that significantly
jeopardized the trial timelines. There were no safety concerns related to the early termination
of the trial. - | ||
| NCT04401995 Details | 2024-02-13 Interventional | 2 | - | Nivolumab Melanoma | Evaluation in process, pending new trial with similar agents - | |||
| NCT04162873 Details | 2024-02-13 Interventional | 2 | - | Celecoxib Carcinoma Head and Neck N… Laryngeal Neopl… Oropharyngeal N… Paranasal Sinus… Recurrence Clinical Stage … Clinical Stage … Nasal Cavity an… Oral Cavity Car… Pathologic Stag… Pathologic Stag… Recurrent Hypop… Recurrent Laryn… Recurrent Nasal… Recurrent Oral … Recurrent Oroph… Stage III Hypop… Stage III Laryn… Stage III Oroph… Stage IV Hypoph… Stage IV Laryng… Stage IV Oropha… Stage IVA Hypop… Stage IVA Laryn… Stage IVA Oroph… Stage IVB Hypop… Stage IVB Laryn… Stage IVB Oroph… Stage IVC Hypop… Stage IVC Laryn… Stage IVC Oroph… | Pending confirmation of additional funding - | |||
| NCT02864953 NCT04950972 2017-004854-41 Details | 2024-02-13 Interventional | 3 | 535 | Glyburide Brain Edema Edema Infarction Stroke Stroke, Acute | Early completed to operational challenges and other strategic considerations, not for efficacy
or safety reasons Early termination of trial due to operational challenges and other strategic considerations, not for efficacy or safety reasons. |